TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
TScan Therapeutics's price to sales ratio was 3.4× on Nov 11, 2026, against 16.8× a year earlier. Over the last 4 years it ranged from 2.0× to 83.5×, with a median of 15.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.4× | −11.7 |
| 2025 | Dec 31, 2025 | 15.1× | −19.1 |
| 2024 | Dec 31, 2024 | 34.3× | +17.9 |
| 2023 | Dec 29, 2023 | 16.4× | +12.9 |
| 2022 | Jan 31, 2022 | 3.5× | +0.2 |
| 2021 | Dec 31, 2021 | 3.3× | – |
See a number that looks wrong?